Hims & Hers officially launched its menopause and perimenopause service, offering personalized plans that include prescription hormone replacement therapies such as estradiol and progesterone to address symptoms like hot flashes and sleep issues, BofA tells investors in a research note. The launch broadens the Hers brand’s reach into a multi-billion-dollar market, supports revenue diversification amid pressure on the men’s segment, and is expected to provide modest financial contributions in Q4 before ramping into 2026. BofA maintains an Underperform rating and $28 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers launches menopause and perimenopause specialty
- Option traders moderately bearish in Hims and Hers Health with shares down 1.29%
- Mixed options sentiment in Hims and Hers Health with shares up 1.3%
- Option traders moderately bearish in Hims and Hers Health with shares down 5.36%
- BofA lowers Q4 sales estimates for Hims & Hers